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Phase III clinical trials on severe sepsis and septic shock published during the past decade have failed to reveal the
superiority of any therapeutic intervention on mortality compared with evolving standards of care, with the
exception of the Early-Goal Directed Therapy reported in 2001. This viewpoint paper presents an analysis of these
studies in order to understand what lessons can be learned and proposes perspectives for future study designs. A
total of 102 studies were selected among clinical trials published in the field of severe sepsis and septic shock from
2001 to 2013, based on the assessment of a therapeutic intervention and mortality as an outcome. Studies were
further selected according to randomized, controlled trial (RCT) quality criteria and analysed according to reported
data. Most (n = 61) were excluded because they did not comply with RCT quality criteria or did not report inclusion
criteria or patient severity (n = 22). The 19 remaining studies were categorized into three groups depending on
whether the intervention assessed led to better, worse, or equivalent outcomes. It appears that the mortality rate in
the control arm, ranging from 17% to 61%, impacted the results, with a benefit reported in the studies with the
highest rates. Both heterogeneous studied populations and uncontrolled diversity of care among participating
centres probably contributed to discrepancies between studies assessing the same intervention. The new challenge
to enhance the probability of decreasing mortality rates should include a more appropriate definition of sepsis
based on more specific criteria involving biomarker use and accurate patient phenotypes.Review
Introduction
PROWESS-SHOCK, the most recently published trial
that assessed the efficacy of activated protein C in septic
shock failed to show any benefit on mortality despite an
apparently appropriate design [1]. This disappointing
failure, the last among many in the field of severe sepsis
trials, prompted our group of intensivists particularly
involved in sepsis research to look at the past decade of
trials from 2001, the publication year of two positive
sepsis clinical trials: the Early Goal guided therapy from
Rivers and colleagues [2] and the PROWESS study [3],
both published in the New England Journal of Medicine.
In order to understand what lessons can be learned from
the past, we focused on the heterogeneity of data,* Correspondence: jean-paul.mira@cch.aphp.fr
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The interpretation is not based on a systematic review of
the literature but reflects a viewpoint in the light of what
we considered as the most relevant studies for the
reasons explained below. Finally, this viewpoint provides
the opportunity to suggest perspectives for future study
designs.Data heterogeneity
Many randomized, controlled trials (RCTs), aiming to
show an improvement of survival in patients with severe
sepsis and septic shock, were performed since the initial
PROWESS study and the seminal Early-Goal Directed
Therapy study, both published in 2001 [2,3], in parallel
with the release and widespread dissemination of the
Surviving Sepsis Campaign guidelines [4].
Studies that address the effect of various strategies on
sepsis- or septic shock-induced mortality were selected
among PubMed indexed publications from 2001 to
2013. The initial search strategy was based on “sepsis” orOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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were then qualified if they assessed at least one therapeutic
intervention on mortality as an outcome. Trials that did
not clearly report inclusion and exclusion criteria were ex-
cluded, as were those that did not comply with standard
RCT quality criteria (e.g., appropriate research questions,
randomization, blinding when relevant and inclusion/
exclusion process) [5] or were not published in peer-
reviewed journals [1-3,6-21]. Among 102 trials that
assessed therapeutic interventions on mortality in sepsis
published since 2001, only 19 were retained for further
analysis (Figure 1).
The selected studies were divided into three categories
regarding the impact of the studied intervention com-
pared with the control arm: better; no difference; or worse
(Table 1). Only 4 of 19 trials reported that the studied
treatment successfully improved primary outcomes
(mainly mortality) of patients with severe sepsis or septicFigure 1 Flow chart of study selection. *RCT quality criteria include: app
subjects to intervention groups, adequate concealment method, no differe
outcomes measured in a valid and reliable way.shock [2,3,6,7]. In fact, most of these high-quality RCTs
(15/19) found either an absence of statistical difference
between the intervention and control groups (7/19) or
a worse impact on at least one primary or secondary
outcome (8/19) (Table 1). Hence, mortality was in-
creased with the use of hydroxyethylstarches (HES) [21]
or by L-NAME administration [16]. The increase in
poor outcomes more often concerned serious adverse
events: HES increased the incidence of renal failure
[17,21], low-dose steroids were associated with a higher
rate of new infections [18], intensive insulin therapy
was reported to increase the risk of hypoglycaemia
[17,20], and dopamine infusion was shown to favour
arrhythmia [15].
It is noteworthy that two [3,7] of the four positive
studies were stopped early at an interim analysis,
which may impact indirect comparison between stud-
ies assessing the same intervention. For instance, theropriate and clearly focused question, randomized assignment of
nce between groups other than the intervention tested, all relevant
Table 1 Comparison of selected randomized, controlled trials assessing the effects of therapeutic interventions on



















Bernard 2001 [3] Drotrecogin alfa (24 h) 30.8 Decreased
mortality
Serious bleeding event
Annane 2002 [6] Hydrocortisone + fludrocortisone (3 h) 63 Decreased
mortality
No difference





Warren 2001 [8] Antithrombin III (6 h) 38.7 No difference No difference No difference
Reinhart 2004 [9] Extracorporeal endotoxin adsorber (24 h) 26 No difference
Heinrich 2006 [10] IG-MA enriched Ig** (not available) 28.2 Not available
Annane 2007 [12] Norepinephrine plus dobutamine (24 h) 34 No difference
Russel 2008 [14] Vasopressin (24 h) 39 No difference
Ranieri 2012 [1] Drotrecogin alfa (24 h) 24.2 No difference
Opal 2013 [15] Eritoran (12 h) 26.9 No difference
Lopez 2004 [16] NO synthase inhibitor LNMA (72 h) 49 Increased
mortality
Low cardiac output Worse
Abraham 2005 [11] Drotrecogin alfa (48 h) 17 No difference Bleeding events
Brunkhorst
2008 [17]
Insulin/pentastarch (12 h) 26 No difference Hypoglycemia
Renal failure
Coagulopathy
Sprung 2008 [18] Hydrocortisone (72 h) 31.5 No difference Increased infections
events
Stephens 2008 [13] G-CSF*** (24 h) 25 No difference Higher rate of new
organ failure
Patel 2010 [19] Dopamine Early goal guided therapy 43 No difference Arrhythmias
Annane 2010 [20] Corticosteroid/Insulin (not available) 45.8 No difference Superinfection
Hypoglycemia
Perner 2012 [21] 6% HES 130/0.42 (24 h) 43 Increased
mortality
Not available
The selected trials were categorized in three groups depending on whether the effect of the studied intervention on mortality and/or serious adverse events was
“better”: studied intervention leading to a significant reduction in mortality; “not different”: similar impact of the studied intervention on mortality and no severe
adverse events; “worse”: studied intervention leading to a significant increase in mortality and/or to a significant increase in serious adverse events.
*Statistically significant difference vs. control arm: **neutropenic patients; ***granulocyte colony-stimulating factor.
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showed a reduction of mortality at day 28, but not at
3 months [1]. In contrast, a study on antithrombin III
showed a trend towards a reduction in 90-day mor-
tality in the high-risk SAPS II stratum, which was not
observed at 28 days [8].
Population and management heterogeneity
When comparing the selected studies, one of the most
striking observations is that overall 28-day mortality
rates in control groups are very heterogeneous, ranging
from 17% [10,11] to 61% [6], despite similar definitions
of severe sepsis and septic shock and very closedinclusion and exclusion criteria. Interestingly, three of
the four positive trials are among the oldest studies and
also are those with the highest mortality rates in the
control group (49-61%). Conversely, negative trials in-
cluded more recent trials with lower mortality rates in
the control arm (17-39%) [2,3,6]. This observation was
confirmed by the latest published phase III study known
as the ACCESS randomized trial [15], which failed to
show any benefit with the infusion of eritoran (a lipid A
antagonist) on 28- or 90-day mortality, with a mortality
rate in the control arm in the low range (26.9%). Another
argument supporting this hypothesis is the comparison
between the PROWESS [2] and PROWESS SHOCK [1]
Table 3 Expected change in (B) relative mortality rates




Decreased in relative mortality rates according to
population sizes (%)
10 20 30 40 50 60 70 80 90
10 26978 6432 2720 1452 880 576 398 286 210
20 12044 2896 1236 666 408 270 190 138 104
30 7050 1714 740 404 250 168 120 88 68
40 4544 1120 490 272 172 118 84 64 50
50 3032 762 340 192 124 86 64 50 40
60 2022 522 238 138 92 66 50 40 32
70 1298 350 166 100 68 50 40 32 26
80 758 220 110 70 50 38 32 26 22
90 352 118 66 46 34 28 24 22 20
Population sizes were calculated from Stata 12.0 software with an absolute α
risk of 5% (bilateral) and a power of 80%.
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PROWESS SHOCK study themselves concluded that they
cannot explain the inconsistency between their findings
and the reduction of mortality at 28 days that was ob-
served in the PROWESS study. The difference in 28-day
mortality rates between the two control populations
was consistent (24.2% vs. 30.8%, respectively), and may
reveal different severity status between the two popula-
tions/periods, and therefore explain the discrepancy in
terms of benefit. Interestingly, such a difference was
close to that observed between intervention and control
groups in the “positive” PROWESS study.
Changes in standards of care over time, essentially based
on new recommendations and guidelines for the manage-
ment of sepsis, have led to a dramatic decrease in mortal-
ity rate of severe sepsis and septic shock during the past
decade [22]. This fact directly impacts sepsis study designs
through the necessary requirement of larger populations
to adequately tailor the power of trials with mortality as a
primary outcome. For instance, a 10% decrease in absolute
mortality rate from a control mortality rate of 30% will
require a sample size of approximately 7,000 patients
(Tables 2 and 3) that has not yet been attained in critical
care trials focused on sepsis.
Additionally, virtually no information is available in
these studies concerning early mortality (within the first 3
days) related to sepsis-induced refractory shock or death
due to withdrawal of care in the context of persisting
organ dysfunctions [23]. Such information might be
important to analyse the direct effect of the tested drug
and to understand the causes of death in ICU.
Another observation is that despite similar definitions
of sepsis, these high-quality studies enrolled patients fol-
lowing varying delays from the onset of septic shock and
organ failure, ranging from less than 2 h [3] to 72 h [18].
The time window ranged from “as soon as possible” to
24 h in the successful studies, whereas it ranged from 12
h to 72 h for the studies with adverse effects of therapy.





Decreased in absolute mortality rates according to
population sizes (%)
5 10 15 20 25 30
10 880 0 0 0 0 0
20 1816 408 162 0 0 0
30 2490 592 250 134 82 0
40 2898 712 310 172 108 74
50 3032 762 340 192 124 86
60 2894 744 338 196 128 92
Population sizes were calculated from Stata 12.0 software with an absolute α
risk of 5% (bilateral) and a power of 80%.were characterized by an early randomization/enrolment
(within the first 24 hours) allowing early interventions.
The most striking example is the Early Goal Directed
Therapy trial, in which patients were enrolled within 2
hours following their arrival at the emergency depart-
ment [3]. This may be a crucial point when testing drugs
that aim to control the inflammatory cascade in the ab-
sence of immunomonitoring. Different delays from onset
to inclusion may partially explain the different results
found by two trials assessing the effects of low-dose ste-
roids [6,18]. Indeed, patients were enrolled within 8 h in
the study of Annane and colleagues reporting an im-
provement in the intervention arm [6], whereas enrol-
ment was allowed within the first 72 h in the study of
Sprung and colleagues reporting a potential deleterious
impact of similar doses of steroids [18].
The analysis of patients’ characteristics reveals that most
of the trials included heterogeneous populations. Inclusion
criteria were essentially based on the 1992 ACCP consen-
sus criteria without any further characterization of sepsis,
and study groups widely varied in terms of aetiology of
infection, severity of illness, organ failures, organ support,
standard of care, and levels of healthcare systems. Further-
more, comorbidities, which have been shown to be major
prognostic factors, were not or poorly reported in most of
these studies [24]. Strikingly, stratification of patients
according to severity scores (APACHE II score, SAPS…)
did not prevent such bias. In a meta-analysis assessing
recombinant human activated protein C and including the
PROWESS and ADDRESS studies, the heterogeneity of
the results (efficacy in the PROWESS study, failure in the
ADDRESS study) was observed even when considering
patients with APACHE II score ≥ 25 [25]. In this respect,
extending the risk-related variables from the systemic in-
flammatory response or the organ dysfunction to a global
personalized approach, such as proposed in the PIRO
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tion of the “good patients to include”.
Overall, the analysis of the selected studies combined
with the authors’ experience in the field of sepsis man-
agement supports the idea that both population het-
erogeneity and uncontrolled diversity of care among
participating centres probably contributed to discrepan-
cies between studies assessing the same intervention.
This interpretation is consistent with the survey on the
type of fluids used for fluid challenge in European ICUs
[27], a study on catecholamine use [28], or the assess-
ment of the adherence to Surviving Sepsis Campaign
recommendations [29].
Finally, it is noteworthy that among the few studies
reporting improved outcomes, all excepted one were
academic and recruited either in a single centre [3] or in
a small number of centres inside a single country [6,7].
In order to decrease the length of the trials and to favour
international development of their product, pharmaceut-
ical companies conducted large international trials, despite
well-known differences in ICU bed availability and life
expectancy (both indirect health system indicators)
around the world. These observations support the need
for improving homogeneity of populations enrolled in
future trials.Conclusions
Although the knowledge of sepsis pathophysiology
continues to dramatically progress, clinical trials in
this field still suffer from major weaknesses mainly due
to heterogeneity. Addressing the major causes of hetero-
geneity remains therefore a major issue.
What lessons have we learned from previous studies
and what could be proposed to improve research in
sepsis? First, “standardized” open-source clinical reporting
forms should be conceived for severe sepsis/septic shock
studies and should be accessible for all future studies. In
an era characterized by the promises of “big-data”, this
would allow massive comprehensive data aggregation into
data warehouses, which could be publically available
through clear usage licenses.
Second, if mortality is to remain a primary endpoint,
trials should be able to recruit only patients with high
mortality risks. However, the use of severity scores and
classical definitions of severe sepsis/septic shock have
all clearly failed to this end. Therefore, an alternative
stratification of patients into high mortality risk groups
by referring to the dynamic rather than the static use of
existing parameters, i.e., persistence and/or worsening
signs of hypoperfusion after adequate infection source
control, goal-directed fluid therapy, and vasopressor
infusion could be recommended. The search for panels
of biomarkers associated with high mortality also couldimprove the selection of patients to be included into
future studies. Likewise and maybe more realistically,
patient phenotypes not to be included in trials because
of good prognosis or absence of ongoing infection
should be identified (for instance, by excluding patients
with normal values of procalcitonin).
Finally, another potential cause for the heterogeneity ob-
served in many studies seldom raised may be intercentre
variability. Indeed, in many recent studies, although enrol-
ment criteria were overall similar, the inclusion rates
varied widely from centre to centre. Centres that enrol too
few patients during a sustained period of time are most
likely exposed to “study pitfalls”, leading to potential bias
and should not be maintained in the study.
Based on our analysis highlighting the heterogeneity of
data reported during the past decade in the field of severe
sepsis and septic shock, the challenge is to set up new ap-
proaches, which should generate more appropriate defini-
tions of sepsis to be used in appropriate study designs
resulting in higher probabilities of showing an impact on
mortality. A recent viewpoint paper [30] stated that the def-
inition of severe sepsis vs. sepsis often is confusing and that
some criteria, such as the degree of organ dysfunction,
should be taken into account in the definition. One key
message is that it is more appropriate to refer to various
and specific sepsis instead of sepsis in general. This nuance
should be taken into account in the definition and selection
of patients to be enrolled.
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